文拉法辛联合艾司西酞普兰治疗老年焦虑症的临床效果及安全性研究

目的 探讨文拉法辛联合艾司西酞普兰治疗老年焦虑症的临床疗效及安全性。方法 选取2015年5月-2018年5月青海省第三人民医院收治的120例老年焦虑症患者，根据其入院顺序随机分为两组，每组各60例，对照组患者给予艾司西酞普兰治疗，初始剂量5 mg/d，后根据患者病情进行调整，剂量控制在10~20 mg/d，每日1次；观察组患者给予文拉法辛联合艾司西酞普兰治疗，初始剂量75 mg/d，后根据患者病情进行调整，最高用量控制在200 mg/d，每日1次。连续治疗1个月。比较两组的治疗效果、汉密尔顿焦虑量表（HAMA）评分及不良反应发生率。结果 观察组治疗总有效率为95.00%，显著高于对照组的81.67%（P<0.05）。治疗后两组HAMA评分均显著低于治疗前（P<0.05），且观察组显著低于对照组（P<0.05）。两组治疗期间口干、恶心呕吐、便秘、头晕等不良反应发生率无显著差异。结论 文拉法辛联合艾司西酞普兰治疗老年焦虑症的疗效显著，可有效缓解患者焦虑症状，且安全性较好。

Clinical effect and safety of escitalopram combined with venlafaxine in treatment of elderly patients with anxiety

Objective To investigate the clinical efficacy and safety of escitalopram combined with venlafaxine in the treatment of senile anxiety. Methods 120 cases of elderly anxiety patients admitted to our hospital from May 2015 to May 2018 were selected as subjects, according to the order of patients admitted to the hospital, they were randomly divided into study group and control group, 60 cases in each group. Patients in the control group were treated with escitalopram, and patients in the study group were given escitalopram combined with venlafaxine. Then the treatment effect, HAMA score and incidence of adverse reactions were compared between the two groups. Results The total effective rate of the study group was significantly higher than that of the control group (P<0.05). After treatment, the HAMA scores of the two groups were significantly lower than before treatment (P<0.05), and the study group was significantly lower than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions such as dry mouth, dizziness, nausea and vomiting, constipation during the two groups. Conclusion Escitalopram combined with venlafaxine has a significant effect in the treatment of senile anxiety, which can effectively alleviate anxiety symptoms and is safer.